The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation.
10.4285/jkstn.2018.32.3.49
- Author:
So Jeong KIM
1
;
Kang Woong JUN
;
Jeong Kye HWANG
;
Byung Ha CHUNG
;
Chul Woo YANG
;
In Sung MOON
;
Ji il KIM
;
Mi Hyeong KIM
Author Information
1. Division of Vascular and Transplant Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. mhkim@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Bortezomib;
Graft rejection;
Immunosuppression;
Kidney transplantation
- MeSH:
Bortezomib*;
Graft Rejection;
Humans;
Immunosuppression;
Kidney Transplantation*;
Kidney*;
Leukocytes;
Survival Rate;
Tissue Donors;
Transplants
- From:The Journal of the Korean Society for Transplantation
2018;32(3):49-56
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to precisely define how the drug affects the clinical course. We used bortezomib to treat eight cases of AMR that developed immediately following KT in patients who were resistant to conventional treatment. METHODS: Eight cases of refractory AMR that developed immediately after KT were treated with bortezomib on days 1, 4, 8, and 11. RESULTS: The resolution rate was 75%, and the 2-year rejection-free survival rate was 83%. Six cases underwent immunologically high-risk KT. Six recovering patients exhibited clinical improvement within 2 weeks of the first dose of bortezomib and recovered completely within 2 months. The effects of bortezomib seemed to be prolonged; only one additional rejection episode was observed. The two failed patients never exhibited any clinical improvement and progressed aggressively to graft failure soon after transplantation. Their donor specific anti-human leukocyte antigen antibody were sustained at high levels. CONCLUSIONS: Bortezomib is an effective rescue therapy in patients with AMR that developed immediately after KT.
